Որոնման արդյունքները - Heinz Gisslinger
- Ցուցադրվում են 1 - 20 արդյունքները 67
- Գնացեք Հաջորդ էջ
-
1
-
2
-
3
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification Jürgen Thiele, Hans Michael Kvasnicka, Leonhard Müllauer, Veronika Buxhofer‐Ausch, Bettina Gisslinger, Heinz Gisslinger
Հրապարակվել է 2011Artigo -
4
-
5
-
6
-
7
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian, Heinz Gisslinger, Jean‐Jacques Kiladjian
Հրապարակվել է 2023Carta -
8
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial Heinz Gisslinger, Mirjana Gotić, Jerzy Hołowiecki, Miroslav Penka, Jüergen Thiele, Hans Michael Kvasnicka, Róbert Královics, Petro E. Petrides
Հրապարակվել է 2013Artigo -
9
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, Hans Michael Kvasnicka, Alessandro M. Vannucchi, Paola Guglielmelli, Attilio Orazi, Ayalew Tefferi
Հրապարակվել է 2018Revisão -
10
Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans Aleksandra E. Kornienko, Christoph Dotter, Philipp Guenzl, Heinz Gisslinger, Bettina Gisslinger, Ciara Cleary, Róbert Královics, Florian M. Pauler, Denise P. Barlow
Հրապարակվել է 2016Artigo -
11
Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia Marco Ruggeri, Heinz Gisslinger, Alberto Tosetto, C. Rintelen, Christine Mannhalter, Ingrid Pabinger, Navide Heis, Giancarlo Castaman, Edoardo Missiaglia, Klaus Lechner, Francesco Rodeghiero
Հրապարակվել է 2002Artigo -
12
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F Franz X. Schaub, Roland Jäger, Renate Looser, Hui Hao-Shen, Sylvie Hermouet, François Girodon, André Tichelli, Heinz Gisslinger, Róbert Královics, Radek C. Skoda
Հրապարակվել է 2008Artigo -
13
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma H. Ludwig, Zdeněk Adam, E Tóthová, Roman Hájek, Boris Labar, Miklós Egyed, Ivan Špıčka, Heinz Gisslinger, Johannes Drach, Ingrid Kühn, Axel Hinke, N. Zojer
Հրապարակվել է 2010Artigo -
14
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Maurizio Ferrari, Heinz Gisslinger, Róbert Královics, Laura Cremonesi, Radek C. Skoda, Mario Cazzola
Հրապարակվել է 2007Artigo -
15
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma Heinz Ludwig, Roman Hájek, Elena Tóthová, Johannes Drach, Zdeněk Adam, Boris Labar, Miklós Egyed, Ivan Špıčka, Heinz Gisslinger, Richard Greil, Ingrid Kühn, Niklas Zojer, Axel Hinke
Հրապարակվել է 2008Artigo -
16
Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study Markus S. Anker, Maria Klara Frey, Georg Goliasch, Philipp E. Bartko, Suriya Prausmüller, Heinz Gisslinger, Gabriela Kornek, Guido Strunk, Markus Raderer, Christoph Zielinski, Martin Hülsmann, Noémi Pávó
Հրապարակվել է 2020Artigo -
17
Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study Heinz Ludwig, Zdeněk Adam, Roman Hájek, Richard Greil, Elena Tóthová, Felix Keil, Eva Maria Autzinger, Josef Thaler, Heinz Gisslinger, Alois Lang, Miklós Egyed, Irene Womastek, Niklas Zojer
Հրապարակվել է 2010Artigo -
18
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis Alessandro M. Vannucchi, Peter te Boekhorst, Claire Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer‐Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, Heinz Gisslinger
Հրապարակվել է 2018Artigo -
19
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b Jean‐Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Róbert Královics, Heinz Gisslinger, Jean‐Jacques Kiladjian, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Heinz Gisslinger
Հրապարակվել է 2022Carta -
20
Masked polycythemia vera diagnosed according to WHO and BCSH classification Tiziano Barbui, Jürgen Thiele, Alessandra Carobbio, Heinz Gisslinger, Guido Finazzi, Elisa Rumi, Maria Luigia Randi, Alessandro M. Vannucchi, Bettina Gisslinger, Leonhard Müllauer, Marco Ruggeri, Alessandro Rambaldi, Ayalew Tefferi
Հրապարակվել է 2013Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Medicine
Internal medicine
Bone marrow
Myelofibrosis
Polycythemia vera
Gastroenterology
Essential thrombocythemia
Biology
Immunology
Surgery
Oncology
Genetics
Gene
Myeloproliferative neoplasm
Ruxolitinib
Cancer research
Pathology
Thrombosis
Chemotherapy
Clinical trial
Cohort
Intensive care medicine
Multiple myeloma
Disease
Mutation
Adverse effect
Clinical endpoint
Confidence interval
Environmental health
Hematology